tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksChatGPT StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Personal Finance CenterMortgagesLoansInvesting & RetirementSpending & Savings
Calculators
401k Retirement CalculatorMortgage Calculator
Popular
Compound Interest CalculatorDollar Cost Averaging
New
Student Loan CalculatorAuto Loan Calculator
Education
How To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksTipRanks CommunityContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsSmart PortfolioExpert CenterTipRanksAI
TOOLS
My Portfolio
My Watchlist
Earnings Calendar
Stock Screener
Penny Stocks
Top Stocks
Daily Analyst Ratings
STOCKS
BABA
AAPL
SPY
AMZN
QQQ
TSLA
NVDA
ADVANCED RESEARCH
TipRanks Premium
Invest Like a Pro with Unique Data & Simplifed ToolsTry Now
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
ChatGPT Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
TipRanks Community
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

APGE Stock Latest News

Spyre Therapeutics price target raised to $54 from $36 at Stifel
The FlySpyre Therapeutics price target raised to $54 from $36 at Stifel
1M ago
APGE
ATXS
Apogee Therapeutics Launches Innovative Antibody Clinical Trial
PremiumCompany Announcements
Apogee Therapeutics Launches Innovative Antibody Clinical Trial
1M ago
8K
APGE
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases
PremiumPress Releases
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases
1M ago
APGE
Apogee announces first participants dosed in Phase 1 trial of APG808
PremiumThe Fly
Apogee announces first participants dosed in Phase 1 trial of APG808
1M ago
APGE
Four new option listings on March 20th
PremiumThe Fly
Four new option listings on March 20th
1M ago
ADTH
APGE
Apogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $483 Million
PremiumPress ReleasesApogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $483 Million
2M ago
APGE
Apogee Therapeutics 6.77M share Secondary priced at $62.00
PremiumThe Fly
Apogee Therapeutics 6.77M share Secondary priced at $62.00
2M ago
APGE
Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public Offering
PremiumPress Releases
Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public Offering
2M ago
APGE
Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering
PremiumPress Releases
Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering
2M ago
APGE
Apogee Therapeutics announces $350M common stock offering
PremiumThe Fly
Apogee Therapeutics announces $350M common stock offering
2M ago
APGE
Apogee Therapeutics files to sell 6M shares of common stock
PremiumThe Fly
Apogee Therapeutics files to sell 6M shares of common stock
2M ago
APGE
Apogee Therapeutics price target raised to $95 from $46 at Stifel
PremiumThe Fly
Apogee Therapeutics price target raised to $95 from $46 at Stifel
2M ago
APGE
Apogee Therapeutics Unveils Promising APG777 Phase 1 Data
PremiumCompany AnnouncementsApogee Therapeutics Unveils Promising APG777 Phase 1 Data
2M ago
8K
APGE
Apogee Therapeutics price target raised to $91 from $44 at Guggenheim
PremiumThe Fly
Apogee Therapeutics price target raised to $91 from $44 at Guggenheim
2M ago
APGE
Apogee Therapeutics Announces Breakthrough Phase 1 Results
PremiumCompany Announcements
Apogee Therapeutics Announces Breakthrough Phase 1 Results
2M ago
8K
APGE
Apogee Therapeutics reports Q4 net loss $31.7M vs. $14M last year
PremiumThe Fly
Apogee Therapeutics reports Q4 net loss $31.7M vs. $14M last year
2M ago
APGE
Apogee Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
PremiumPress Releases
Apogee Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
2M ago
APGE
Apogee Therapeutics’ APG777 shows positive Phase 1 results in dermatitis
PremiumThe Fly
Apogee Therapeutics’ APG777 shows positive Phase 1 results in dermatitis
2M ago
APGE
Apogee Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases, Exceeding its Trial Objectives Ahead of Schedule with Half-Life of Approximately 75 Days
PremiumPress Releases
Apogee Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases, Exceeding its Trial Objectives Ahead of Schedule with Half-Life of Approximately 75 Days
2M ago
APGE
Apogee to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases on March 5, 2024
PremiumPress ReleasesApogee to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases on March 5, 2024
2M ago
APGE
Spyre Therapeutics price target raised to $36 from $27 at Stifel
PremiumThe Fly
Spyre Therapeutics price target raised to $36 from $27 at Stifel
4M ago
GSK
APGE
Apogee Therapeutics price target raised to $46 from $34 at Stifel
PremiumThe Fly
Apogee Therapeutics price target raised to $46 from $34 at Stifel
4M ago
GSK
APGE

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >